Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Kaleta, Agnieszka" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
SILDENAFIL UPREGULATES TUMOR NECROSIS FACTOR α PRODUCTION IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF HEALTHY MEN - PRELIMINARY REPORT
Autorzy:
Kaleta, Beata
Boguska, Agnieszka
Borysowski, Jan
Górski, Andrzej
Powiązania:
https://bibliotekanauki.pl/articles/895585.pdf
Data publikacji:
2019-02-28
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
cytokines
tumor necrosis factor alpha
Sildenafil
peripheral blood mononuclear cells
Opis:
Sildenafil is a selective type 5 phosphodiesterase (PDE5) inhibitor, commonly used in the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). The results of recent studies suggest that this drug modulates function of the immune system. However, only few studies were performed in humans. Therefore, the aim of this study was to investigate the ability of sildenafil to regulate the production of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β and IL-6 in peripheral blood mononuclear cells (PBMCs) from healthy men. Phorbol myristate acetate (PMA) - stimulated and unstimulated PBMCs from 16 participants were cultured in the absence or presence of sildenafil (400 ng/ml and 4 µg/ml). TNF-α, IL-1β and IL-6 concentrations in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). Cell viability was assessed by trypan blue staining. Sildenafil at a concentration of 400 ng/ml significantly increased TNF-α production in stimulated PBMCs (p<0.05) but had no effects on IL-1β and IL-6. The drug did not affect PBMCs viability. This is the first report describing such effects of sildenafil in humans.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 1; 123-128
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Levels of interleukin-2 in patients with colon cancer and diabetes type 2
Autorzy:
Bosek, Irina
Sulich, Agnieszka
Rabijewski, Michał
Kaleta, Beata
Kniotek, Monika
Miłek, Tomasz
Piątkiewicz, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/972606.pdf
Data publikacji:
2016
Wydawca:
Instytut Medycyny Wsi
Tematy:
diabetes type 2
colon cancer
interleukin-2
Opis:
Introduction and objective: The risk of development colon cancer (CC) is increased significantly among patients with the type 2 diabetes (T2DM). A mechanism responsible for the higher prevalence of CC among diabetic patients may be associated with the immunity system. The aim of this study is to point out the differences in the immunity state in terms of interleukin 2 level among patients with T2DM suffering from CC, and patients without these diseases Material and Methods: 79 patients were included the tests, divided into 4 groups: Group 1–23 people with T2DM, Group 2–23 people with large intestine CC, Group 3–10 people with large CC and T2DM, and Group 4–23 people without T2DM or CC. Each patient had a colonoscopy and those with cancer were confirmed in a histopathological examination. Laboratory measurements included fasting glucose, insulin, C-peptide. The concentration of interleukin-2 in serum was determined with the immunoenzymatic (ELISA) method. Results: The results obtained showed that in patients with T2DM and CC the concentration of interleukin-2 was statistically higher than in the other groups.(4.21±1.61 pg/ml vs. Group 1 -1.64±0.44 pg/ml, Group 2–1.54±0.21 pg/ml, and Group 4–1.70±0.36 pg/ml; p<0.05). Insulin levels, C-peptide and HOMA-IR did not differ significantly between groups, but a tendency was observed to higher values of HOMA-IR and insulin levels in the groups with T2DM alone and T2DM with concomitant CC. Conclusions: The data show differences in the immunity state of patients with T2DM and CC, compared with people without those two diseases. Elevated level of interleukin 2 found in this group, after confirmation in other studies with more patients, could be used as a marker of an increased risk of CC in people with T2DM
Źródło:
Journal of Pre-Clinical and Clinical Research; 2016, 10, 1; 1-5
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies